Eleven Biotherapeutics (EBIO) Reports Q4 Loss of $0.15/Share

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q4 EPS of ($0.15), versus ($0.53) reported last year. Revenue for the quarter came in at $825 thousand, versus $565 thousand reported last year.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• HSBC Upgrades Blue Star Limited (BLSTR:IN) to Buy
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance